# AriBio, Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aribio-co

- Industry: Biotechnology
- Headquarters: Seongnam, South Korea
- Website: www.aribio.com
- Total disclosed funding: $3.5M
- Latest round: Series B (Nov 14, 2014)
- Investors on record: 2

## About

Based in Seongnam, South Korea, and founded in 2010, AriBio develops an artificial intelligence-powered, reserve-engineered, and integrated drug development (AIRDD) platform for neurodegenerative diseases. In January 2022, AriBio raised KRW 34.5 billion in pre-IPO funding from Mason Capital and Cactus Private Equity. As of January 2024, the company is led by CEO Jai Jun Choung.


The business offers an AIRDD multi-mechanism medication for neurodegenerative disorders like Alzheimer's, which are caused by a combination of hereditary, environmental, and psychological factors. The platform uses AI to engage drugs across various targets and mechanisms in a large chemical database. The company's solutions for Alzheimer's disease, prodromal illness, and rent syndrome are in the enabling stage, while moderate cognitive impairment and dementia with lewy bodies are in phase 2.

## Funding rounds

- Series B, Nov 14, 2014, $3.5M — WOORI Venture Partners, Korea Credit Guarantee Fund

## Investors

- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series B
- Korea Credit Guarantee Fund — Series B